文献速递临床试验与 GCP

OPAL:一项旨在减轻急性脊柱疼痛患者疼痛严重程度的阿片类镇痛药随机安慰剂对照试验——统计分析计划

OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain-a statistical analysis plan.
PubMed 文献 · Trials · 2022-03-14

OPAL试验为前瞻性注册、三盲、随机、安慰剂对照试验,纳入急性(≤12周)背痛和/或颈痛患者,在接受指南诊疗基础上随机加用阿片类药物(羟考酮+纳洛酮,每日最多20 mg)或安慰剂,最长6周或疼痛缓解即停。主要结局为简明疼痛量表疼痛严重程度评分第6周值,按意向性治疗原则分析。本文为预先设定的统计分析计划。

要点

  • OPAL试验采用三盲、随机、安慰剂对照设计,评估短程阿片类药物对急性非特异性背痛和/或颈痛的疗效。
  • 主要结局为简明疼痛量表疼痛严重程度评分第6周值,按意向性治疗原则分析。
  • 次要结局包括躯体功能、恢复时间、生活质量、不良事件及阿片类药物误用风险,于第2、4、6、12、26、52周收集。

核心结论

  • OPAL试验将提供重要证据,说明短程阿片类药物治疗急性非特异性背痛和/或颈痛是否有效。
  • 本预先设定的统计分析计划详细说明了OPAL试验结果分析的方法学。

研究设计与样本

  • OPAL试验为前瞻性注册、三盲、随机、安慰剂对照试验。
  • 纳入急性(≤12周)背痛和/或颈痛患者,接受指南诊疗加阿片类药物(羟考酮+纳洛酮,每日最多20 mg)或安慰剂,最长6周或疼痛缓解即停。
  • 主要结局为简明疼痛量表疼痛严重程度评分,主要时间点为第6周。
  • 次要结局包括躯体功能、恢复时间、生活质量、不良事件及阿片类药物误用风险,于第2、4、6、12、26、52周收集。
  • 分析按意向性治疗原则进行,p值<0.05视为显著,报告95%置信区间。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low back and neck pain are a leading cause of disease burden globally. Opioids are recommended in guidelines for acute low back and neck pain; however, there is a lack of compelling efficacy data to support this. METHODS: The OPAL trial is a prospectively registered, triple-blinded, randomised, placebo-controlled trial. Patients with acute (≤12 weeks duration) back and/or neck pain receive guideline care plus either an opioid (oxycodone + naloxone, up to 20 mg per day) or a placebo for up to 6 weeks or earlier, if pain is resolved. The primary outcome is pain measured using the Pain Severity Score of the Brief Pain Inventory with the primary time point being 6 weeks. Secondary outcomes include physical function, time to recovery, quality of life, adverse events and risk of opioid misuse. Outcomes are collected at weeks 2, 4, 6, 12, 26 and 52. Analysis will be done on an intention-to-treat principle. p values of < 0.05 will be considered significant and 95% confidence intervals will be reported. Repeated-measures linear mixed models will be used to assess the effect of the treatment group on the primary outcome and continuous secondary outcomes. Adverse events will be compared between groups using Fisher's exact test. Cost-effectiveness analyses will be conducted if a treatment effect on pain is seen at week 6. Subgroup analyses will be performed to assess whether pain duration and pain location are treatment effect modifiers. DISCUSSION: The OPAL trial will provide important evidence about whether a short course of opioids is effective in the treatment of acute non-specific low back and/or neck pain. This pre-specified statistical analysis plan details the methodology for the analysis of the OPAL trial results. TRIAL REGISTRATION: ACTRN12615000775516 . The trial has completed recruitment. Follow-up on the last patient will be completed in March 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jones CM, Lin CC, Day RO, et al. OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain-a statistical analysis plan. Trials. 2022. PMID: 35287698. doi:10.1186/s13063-022-06028-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。